المؤلفون: Başcı S; Department of Hematology and Bone Marrow Transplantation Center, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey., Ata N; Department of Strategy Development, Ministry of Health, Republic of Turkey, Ankara, Turkey., Altuntaş F; Department of Hematology and Bone Marrow Transplantation Center, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey., Yiğenoğlu TN; Department of Hematology and Bone Marrow Transplantation Center, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey., Dal MS; Department of Hematology and Bone Marrow Transplantation Center, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey., Korkmaz S; Department of Hematology, Kayseri City Hospital, University of Health Sciences, Kayseri, Turkey., Namdaroğlu S; Department of Hematology, Bozyaka Training and Research Hospital, University of Health Sciences, Izmir, Turkey., Baştürk A; Division of Hematology, Department of Internal Medicine, School of Medicine, Selçuk University, Konya, Turkey., Hacıbekiroğlu T; Division of Hematology, Department of Internal Medicine, School of Medicine, Sakarya University, Sakarya, Turkey., Doğu MH; Department of Hematology, İstanbul Training and Research Hospital, İstanbul, Turkey., Berber İ; Division of Hematology, Department of Internal Medicine, School of Medicine, İnönü University, Malatya, Turkey., Dal K; Department of Internal Medicine, Keçiören Training and Research Hospital, Ankara, Turkey., Erkurt MA; Division of Hematology, Department of Internal Medicine, School of Medicine, İnönü University, Malatya, Turkey., Turgut B; Division of Hematology, Department of Internal Medicine, School of Medicine, Namık Kemal University, Tekirdağ, Turkey., Çağlayan M; Ankara Provincial Health Directorate, Ministry of Health, Republic of Turkey, Ankara, Turkey., Ayvalı MO; General Directorate of Health Information Systems, Ministry of Health, Republic of Turkey, Ankara, Turkey., Çelik O; Public Hospitals General Directorate, Ministry of Health, Republic of Turkey, Ankara, Turkey., Ülgü MM; General Directorate of Health Information Systems, Ministry of Health, Republic of Turkey, Ankara, Turkey., Birinci Ş; Deputy Minister of Health, Republic of Turkey, Ankara, Turkey.

مؤلفون مشاركون: Turkish Ministry of Health, Hematology Scientific Working Group

المصدر: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2020 Oct; Vol. 26 (7), pp. 1676-1682. Date of Electronic Publication: 2020 Aug 27.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: SAGE Publications Country of Publication: England NLM ID: 9511372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-092X (Electronic) Linking ISSN: 10781552 NLM ISO Abbreviation: J Oncol Pharm Pract Subsets: MEDLINE

مواضيع طبية MeSH: Coronavirus Infections*/drug therapy , Coronavirus Infections*/epidemiology , Coronavirus Infections*/physiopathology , Coronavirus Infections*/therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/epidemiology , Pandemics* , Pneumonia, Viral*/epidemiology , Pneumonia, Viral*/physiopathology , Pneumonia, Viral*/therapy, Betacoronavirus/*isolation & purification , Imatinib Mesylate/*administration & dosage , Length of Stay/*statistics & numerical data, Antineoplastic Agents/administration & dosage ; COVID-19 ; Female ; Hospitalization/statistics & numerical data ; Humans ; Male ; Middle Aged ; Outcome and Process Assessment, Health Care ; Protein Kinase Inhibitors/administration & dosage ; Respiration, Artificial/statistics & numerical data ; Retrospective Studies ; SARS-CoV-2 ; Severity of Illness Index ; Turkey/epidemiology ; COVID-19 Drug Treatment